FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765735024> ?p ?o ?g. }

• W2765735024 endingPage "135" @default.
• W2765735024 startingPage "123" @default.
• W2765735024 abstract "To compare anti-TNF dose escalation, DMARD and/or glucocorticoid intensification, switches to another biologic, and drug and drug-related costs over 12 and 18 months for rheumatoid arthritis (RA) patients initiating etanercept (ETN), adalimumab (ADA), or infliximab (IFX) in routine clinical practice across Canada.A retrospective chart review of biologic-naïve adult RA patients newly initiating ADA, ETN, or IFX between January 01, 2006 and December 31, 2012 from 11 practices across Canada.There were 314 patients in the 12-month analysis and 217 in the 18-month analysis. No dose escalation occurred with ETN over 12 and 18 months versus 38% and 32% for IFX (p<0.001) and 2% and 2% for ADA (p=0.199, p=0.218). Over 18 months, dose escalation and/or DMARD and/or glucocorticoid intensification was less frequent among ETN (16%) versus IFX (44%, p=0.005) and ADA (34%, p=0.004). By 18 months, 22% of patients initiating ADA had switched to another biologic compared with 6% of ETN patients (p=0.001).Patients initiating ETN had lower total (drug and drug-related) costs over 12 and 18 months compared to IFX, and no difference compared to ADA when adjusted for potential confounders. Patients with dose escalation had higher costs compared to those with no dose escalation.Physicians were more likely to escalate the dose of IFX, but optimize co-therapy with ADA and ETN. ETN patients had no dose escalation and were less likely to have DMARD and/or glucocorticoid intensification than ADA patients. ETN-treated patients had lower costs compared to IFX patients." @default.
• W2765735024 created "2017-11-10" @default.
• W2765735024 creator A5008817750 @default.
• W2765735024 creator A5023988126 @default.
• W2765735024 creator A5030150540 @default.
• W2765735024 creator A5051689016 @default.
• W2765735024 creator A5065367954 @default.
• W2765735024 creator A5072810056 @default.
• W2765735024 creator A5079946212 @default.
• W2765735024 creator A5085025467 @default.
• W2765735024 date "2017-10-24" @default.
• W2765735024 modified "2023-10-16" @default.
• W2765735024 title "Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study" @default.
• W2765735024 cites W1511613869 @default.
• W2765735024 cites W1517981661 @default.
• W2765735024 cites W159282500 @default.
• W2765735024 cites W1897160555 @default.
• W2765735024 cites W1964049759 @default.
• W2765735024 cites W2015215846 @default.
• W2765735024 cites W2017082386 @default.
• W2765735024 cites W2019460882 @default.
• W2765735024 cites W2021719111 @default.
• W2765735024 cites W2034790774 @default.
• W2765735024 cites W2038593306 @default.
• W2765735024 cites W2040885876 @default.
• W2765735024 cites W2068616072 @default.
• W2765735024 cites W2083673654 @default.
• W2765735024 cites W2085411350 @default.
• W2765735024 cites W2087204357 @default.
• W2765735024 cites W2088684279 @default.
• W2765735024 cites W2108271686 @default.
• W2765735024 cites W2111046066 @default.
• W2765735024 cites W2112234440 @default.
• W2765735024 cites W2119046820 @default.
• W2765735024 cites W2129841863 @default.
• W2765735024 cites W2141171232 @default.
• W2765735024 cites W2142632855 @default.
• W2765735024 cites W2148957059 @default.
• W2765735024 cites W2149065814 @default.
• W2765735024 cites W2414355470 @default.
• W2765735024 cites W2992198512 @default.
• W2765735024 cites W2993649754 @default.
• W2765735024 cites W4250123951 @default.
• W2765735024 doi "https://doi.org/10.2174/1874312901711010123" @default.
• W2765735024 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5744265" @default.
• W2765735024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29296125" @default.
• W2765735024 hasPublicationYear "2017" @default.
• W2765735024 type Work @default.
• W2765735024 sameAs 2765735024 @default.
• W2765735024 citedByCount "4" @default.
• W2765735024 countsByYear W27657350242019 @default.
• W2765735024 countsByYear W27657350242021 @default.
• W2765735024 countsByYear W27657350242023 @default.
• W2765735024 crossrefType "journal-article" @default.
• W2765735024 hasAuthorship W2765735024A5008817750 @default.
• W2765735024 hasAuthorship W2765735024A5023988126 @default.
• W2765735024 hasAuthorship W2765735024A5030150540 @default.
• W2765735024 hasAuthorship W2765735024A5051689016 @default.
• W2765735024 hasAuthorship W2765735024A5065367954 @default.
• W2765735024 hasAuthorship W2765735024A5072810056 @default.
• W2765735024 hasAuthorship W2765735024A5079946212 @default.
• W2765735024 hasAuthorship W2765735024A5085025467 @default.
• W2765735024 hasBestOaLocation W27657350241 @default.
• W2765735024 hasConcept C126322002 @default.
• W2765735024 hasConcept C167135981 @default.
• W2765735024 hasConcept C17991360 @default.
• W2765735024 hasConcept C2776056953 @default.
• W2765735024 hasConcept C2777138892 @default.
• W2765735024 hasConcept C2777226972 @default.
• W2765735024 hasConcept C2777575956 @default.
• W2765735024 hasConcept C2780132546 @default.
• W2765735024 hasConcept C71924100 @default.
• W2765735024 hasConceptScore W2765735024C126322002 @default.
• W2765735024 hasConceptScore W2765735024C167135981 @default.
• W2765735024 hasConceptScore W2765735024C17991360 @default.
• W2765735024 hasConceptScore W2765735024C2776056953 @default.
• W2765735024 hasConceptScore W2765735024C2777138892 @default.
• W2765735024 hasConceptScore W2765735024C2777226972 @default.
• W2765735024 hasConceptScore W2765735024C2777575956 @default.
• W2765735024 hasConceptScore W2765735024C2780132546 @default.
• W2765735024 hasConceptScore W2765735024C71924100 @default.
• W2765735024 hasIssue "1" @default.
• W2765735024 hasLocation W27657350241 @default.
• W2765735024 hasLocation W27657350242 @default.
• W2765735024 hasLocation W27657350243 @default.
• W2765735024 hasLocation W27657350244 @default.
• W2765735024 hasOpenAccess W2765735024 @default.
• W2765735024 hasPrimaryLocation W27657350241 @default.
• W2765735024 hasRelatedWork W1555548379 @default.
• W2765735024 hasRelatedWork W1973470095 @default.
• W2765735024 hasRelatedWork W1976481621 @default.
• W2765735024 hasRelatedWork W1979251453 @default.
• W2765735024 hasRelatedWork W1987798738 @default.
• W2765735024 hasRelatedWork W1993992685 @default.
• W2765735024 hasRelatedWork W2341567294 @default.
• W2765735024 hasRelatedWork W2416182167 @default.
• W2765735024 hasRelatedWork W2463309567 @default.
• W2765735024 hasRelatedWork W4200063390 @default.

• next